君实生物(01877)：VV116对比PAXLOVID早期治疗轻中度COVID-19的III期注册临床研究达到主要研究终点

智通财经2022-05-23

智通财经APP讯，君实生物(01877)发布公告，公司控股子公司上海君拓生物医药科技有限公司与苏州旺山旺水生物医药有限公司合作开发的产品口服核苷类抗SARS-CoV-2药物VV116片(项目代号： JT001/VV116，“VV116”)在一项对比奈玛特韦片╱利托那韦片(即PAXLOVID)用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究 (NCT05341609)达到方案预设的主要终点。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2237331031?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-05-23 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2237331031","market":"us","top_or_hot":-1,"title":"君实生物(01877)：VV116对比PAXLOVID早期治疗轻中度COVID-19的III期注册临床研究达到主要研究终点","media":"智通财经","content":"<div>\n<p>智通财经APP讯，君实生物(01877)发布公告，公司控股子公司上海君拓生物医药科技有限公司与苏州旺山旺水生物医药有限公司合作开发的产品口服核苷类抗SARS-CoV-2药物VV116片(项目代号： JT001/VV116，“VV116”)在一项对比奈玛特韦片╱利托那韦片(即PAXLOVID)用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究 (NCT05341609)达到方案预设的主要终点。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/727788.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物(01877)：VV116对比PAXLOVID早期治疗轻中度COVID-19的III期注册临床研究达到主要研究终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物(01877)：VV116对比PAXLOVID早期治疗轻中度COVID-19的III期注册临床研究达到主要研究终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-23 22:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/727788.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，君实生物(01877)发布公告，公司控股子公司上海君拓生物医药科技有限公司与苏州旺山旺水生物医药有限公司合作开发的产品口服核苷类抗SARS-CoV-2药物VV116片(项目代号： JT001/VV116，“VV116”)在一项对比奈玛特韦片╱利托那韦片(即PAXLOVID)用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究 (NCT05341609)达到方案预设的主要终点。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/727788.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/727788.html","article_id":"2237331031","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2237331031","pubTimestamp":1653317787,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，君实生物(01877)发布公告，公司控股子公司上海君拓生物医药科技有限公司与苏州旺山旺水生物医药有限公司合作开发的产品口服核苷类抗SARS-CoV-2药物VV116片(项目代号： JT001/VV116，“VV116”)在一项对比奈玛特韦片╱利托那韦片(即PAXLOVID)用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究 (NCT05341609)达到方案预设的主要终点。公司将于近期与监管部门沟通递交新药上市申请事宜。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","BK1515":"抗疫概念","III":"信息服务","01877":"君实生物","BK1161":"生物科技","BK4535":"淡马锡持仓","BK4139":"生物科技","BNTX":"BioNTech SE","BK4568":"美国抗疫概念","BK1583":"高瓴概念","BK4134":"信息科技咨询与其它服务","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓"},"translate_title":"Junshi Bio (01877): The phase III registered clinical study of VV116 versus PAXLOVID in early treatment of mild to moderate COVID-19 reached the main study endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1,"BNTX":1,"III":1},"content_text":"智通财经APP讯，君实生物(01877)发布公告，公司控股子公司上海君拓生物医药科技有限公司与苏州旺山旺水生物医药有限公司合作开发的产品口服核苷类抗SARS-CoV-2药物VV116片(项目代号： JT001/VV116，“VV116”)在一项对比奈玛特韦片╱利托那韦片(即PAXLOVID)用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究 (NCT05341609)达到方案预设的主要终点。公司将于近期与监管部门沟通递交新药上市申请事宜。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2237331031"}